Rain Therapeutics Inc. (RAIN): Price and Financial Metrics


Rain Therapeutics Inc. (RAIN): $8.98

-0.70 (-7.23%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RAIN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

RAIN Stock Price Chart Interactive Chart >

Price chart for RAIN

RAIN Price/Volume Stats

Current price $8.98 52-week high $14.48
Prev. close $9.68 52-week low $2.15
Day low $8.80 Volume 232,860
Day high $10.47 Avg. volume 286,473
50-day MA $8.28 Dividend yield N/A
200-day MA $5.82 Market Cap 238.55M

Rain Therapeutics Inc. (RAIN) Company Bio


Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is RAIN-32, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing RAIN-32 that has completed Phase II clinical trial in liposarcoma, Phase I clinical trial in solid tumors, and Phase II clinical trial in intimal sarcoma, as well as RAD52 for tumors, including breast, ovarian, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.


RAIN Latest News Stream


Event/Time News Detail
Loading, please wait...

RAIN Latest Social Stream


Loading social stream, please wait...

View Full RAIN Social Stream

Latest RAIN News From Around the Web

Below are the latest news stories about RAIN THERAPEUTICS INC that investors may wish to consider to help them evaluate RAIN as an investment opportunity.

Phase 1 Clinical Data of Milademetan Published in Journal of Clinical Oncology

– Intermittent dosing of milademetan, an inhibitor of the p53-MDM2 complex, potentially exhibits an avenue to address historical issues with cytopenias with this class of compounds– – Phase 1 data in advanced dedifferentiated liposarcoma provides foundation for the registrational Phase 3 MANTRA trial – NEWARK, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate, mi

Yahoo | January 23, 2023

We Think Rain Oncology (NASDAQ:RAIN) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Yahoo | January 6, 2023

Rain Oncology Could See Sunny Days Ahead

The oncology company's stock has been correcting sideways for a few months but seems poised for renewed gains.

Yahoo | January 5, 2023

Rain Therapeutics Inc. Announces Name Change to Rain Oncology Inc.

NEWARK, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (“Rain”) (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that it will change its name to Rain Oncology Inc. effective tomorrow, December 30, 2022, to better reflect the company's focus on addressing unmet needs for cancer patients

Yahoo | December 29, 2022

Rain Therapeutics to Participate in the 41st Annual J.P. Morgan Health Care Conference

NEWARK, Calif., Dec. 27, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that it will be participating in J.P. Morgan’s 41st Annual Health Care Conference, being held January 9 – 12, 2023, in San Francisco, CA. Avanish Vellanki, chief executive officer o

Yahoo | December 27, 2022

Read More 'RAIN' Stories Here

RAIN Price Returns

1-mo 12.25%
3-mo 52.20%
6-mo 26.48%
1-year 4.66%
3-year N/A
5-year N/A
YTD 12.25%
2022 -37.89%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6547 seconds.